{
    "nct_id": "NCT03322540",
    "official_title": "A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of stage IV NSCLC without epidermal growth factor receptor (EGFR)-sensitizing mutation, ROS1 and/or anaplastic lymphoma kinase (ALK) translocation.\n* Measurable disease based on RECIST 1.1.\n* Tumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ≥ 50% of tumor cells (tumor proportion score [TPS] ≥ 50%) as assessed by immunohistochemistry at a central laboratory.\n* Life expectancy of at least 3 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function per protocol-defined criteria.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known untreated central nervous system metastases and/or carcinomatous meningitis.\n* History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.\n* Symptomatic ascites or pleural effusion.\n* Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Has had an allogeneic tissue/solid organ transplant.\n* Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.\n* Has known history of or is positive for active Hepatitis B (HBsAg reactive) or has active Hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.\n* History or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful.\n* Use of protocol-defined prior/concomitant therapy.",
    "miscellaneous_criteria": ""
}